These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30764089)

  • 21. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Nauck M
    Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
    Triplitt C; Wright A; Chiquette E
    Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition.
    Dokken B
    J Cardiovasc Nurs; 2016; 31(3):274-83. PubMed ID: 25829138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The importance of beta-cell management in type 2 diabetes.
    Standl E
    Int J Clin Pract Suppl; 2007 Jun; (153):10-9. PubMed ID: 17594389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.
    Knop FK; Holst JJ; Vilsbøll T
    IDrugs; 2008 Jul; 11(7):497-501. PubMed ID: 18600596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time to insulin in type-2 diabetes: high hurdles or Santiago way?
    Rotella CM; Pala L
    Acta Diabetol; 2008 Jun; 45(2):67-74. PubMed ID: 18408882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus.
    He ZX; Zhou ZW; Yang Y; Yang T; Pan SY; Qiu JX; Zhou SF
    Clin Exp Pharmacol Physiol; 2015 Feb; 42(2):125-38. PubMed ID: 25360831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The incretin effect: a new therapeutic target in type 2 diabetes].
    Féry F
    Rev Med Brux; 2007 Sep; 28(4):329-35. PubMed ID: 17958029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Incretin modulators, a new perspective in diabetes mellitus treatment].
    Lupaşcu FG; Geangalău IM; Pânzariu A; Profire L
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):630-4. PubMed ID: 23077965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New therapeutic approaches in type 2 diabetes.
    Scheen AJ
    Acta Clin Belg; 2008; 63(6):402-7. PubMed ID: 19170358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Significance of the regulation of hyperglucagonemia in type 2 diabetes mellitus].
    Miuchi M; Miyagawa J; Namba M
    Nihon Rinsho; 2015 Dec; 73(12):1988-94. PubMed ID: 26666142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protection of pancreatic beta-cells: is it feasible?
    Bonora E
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Type 2 diabetes mellitus: pathogenesis and genetic diagnosis.
    Himanshu D; Ali W; Wamique M
    J Diabetes Metab Disord; 2020 Dec; 19(2):1959-1966. PubMed ID: 33520871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. beta-cell function and anti-diabetic pharmacotherapy.
    Del Prato S; Bianchi C; Marchetti P
    Diabetes Metab Res Rev; 2007 Oct; 23(7):518-27. PubMed ID: 17883249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.
    Hanefeld M
    Int J Clin Pract Suppl; 2007 Jun; 61(153):20-7. PubMed ID: 17594390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action.
    Grams J; Garvey WT
    Curr Obes Rep; 2015 Jun; 4(2):287-302. PubMed ID: 26627223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?
    van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S37-46. PubMed ID: 21864750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.